Key facts
- This page summarizes Gregory S. Martin's Form 4/A - Amendment filing for Ionetix Corp / DE /.
- 8 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 13 May 2026, 14:29.
Key filing fact
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Award
Award
Award
Award
Additional SEC filing notes
Footnote F1
Received in connection with the Issuer's merger (the "Merger") with Ionetix Corporation ("Legacy Ionetix") in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of April 9, 2026 (the "Merger Agreement"), by and among the Issuer (f/k/a JDEV Acquisition Corp.), JDEV Merger Subsidiary and Legacy Ionetix. Pursuant to the terms of the Merger Agreement, each outstanding share of Legacy Ionetix common stock was entitled to receive 0.5014 shares of the Issuer's Common Stock. The Merger closed on April 9, 2026.
Footnote F2
Shares held of record by Shamrock Ionetix LLC. The Reporting Person's interest in Shamrock Ionetix LLC consists of a capital investment and a profits (carried) interest entitling the Reporting Person to up to 10% of the profits realized by Shamrock Ionetix LLC on its investment in Ionetix. The 123,767 shares reported in Table I represent the post-Merger equivalent of Shamrock Ionetix LLC's Legacy Ionetix holdings (229,375 shares of Series E Preferred Stock, 14,452 shares of Series F Preferred Stock, and 3,016 shares of Common Stock), converted at the 0.5014 Conversion Ratio pursuant to the Merger Agreement.
Footnote F3
Voting and investment power over the securities held by Shamrock Ionetix LLC is held solely by Stanley P. Gold. The Reporting Person disclaims beneficial ownership of the securities held by Shamrock Ionetix LLC except to the extent of his pecuniary interest therein.
Footnote F4
The stock option is fully vested and exercisable.
Footnote F5
Received in connection with the Merger in exchange for options to acquire shares of Legacy Ionetix common stock adjusted by the Conversion Ratio.
Footnote F6
The stock option vests in 48 monthly installments, subject to a one-year cliff, with vesting commencing on March 17, 2024.
Footnote F7
The stock option vests in 48 monthly installments, subject to a one-year cliff, with vesting commencing on March 17, 2023.
Footnote F8
The stock option vests in 48 monthly installments, subject to a one-year cliff, with vesting commencing on March 17, 2025.
Footnote F9
The warrant is fully vested and exercisable. The warrant was assumed by the Issuer in the Merger described in footnote (1) and is exercisable solely for shares of the Issuer's Common Stock.